A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Our objective was to compare 111In-labeled human epidermal growth factor (hEGF), a 53-amino acid peptide with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) 528 (IgG2a) for imaging EGFR-positive breast cancer. METHODS: hEGF and MAb 528 were derivatized with diethylenetriamine...
Prif Awduron: | Reilly, R, Kiarash, R, Sandhu, J, Lee, Y, Cameron, R, Hendler, A, Vallis, K, Gariépy, J |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
2000
|
Eitemau Tebyg
-
111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
gan: Reilly, R, et al.
Cyhoeddwyd: (2000) -
In-111-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR
gan: Reilly, R, et al.
Cyhoeddwyd: (2000) -
Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells.
gan: Chen, P, et al.
Cyhoeddwyd: (2002) -
The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
gan: Chen, P, et al.
Cyhoeddwyd: (2001) -
Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.
gan: Wang, J, et al.
Cyhoeddwyd: (2001)